Northeast Node of the Clinical Trials Network

Northeast Node of the Clinical Trials Network The Northeast Node of the National Drug Abuse Treatment Clinical Trials Network was founded in 2015 a

The Northeast Node of the National Drug Abuse Treatment Clinical Trials Network (CTN) is based out of Dartmouth College and includes a broad array of researchers, over 400 adult and adolescent general medical care partners, as well as other clinical, quality improvement, policy, regulatory and payer partners across the rural states of New Hampshire, Maine and Vermont. The Northeast Node is affiliated with the NIDA-funded Center for Technology and Behavioral Health (CTBH), which is a P30 “Center of Excellence.”

The Northeast Node team has extensive experience in all stages of SUD intervention development, ranging from feasibility, acceptability, efficacy, efficacy-effectiveness, effectiveness (including multi-site effectiveness trials), cost-effectiveness, and implementation research in many contexts, including addiction and mental health specialty programs, medical specialty programs, hospitals, schools, criminal justice settings, and primary care. This work has included research on the integration of SUD interventions (including technology-based interventions) into health care systems. This work has been conducted with a wide array of populations including chronic drug users, smokers, veterans, chronic pain patients, persons at risk for/living with HIV, and persons with co-occurring SUDs and mental illness. This team also has considerable experience conducting research with youth, including several lines of research focused on cannabis use and prescription opioid use disorders among youth. As part of its activities, the Northeast Node will develop and support an infrastructure to enhance synergy and support bidirectional sharing of knowledge and resources between the NIDA-supported CTBH and the national CTN to inform science-based approaches for leveraging technology in the screening, prevention, treatment, recovery support, and care coordination of substance use disorders, with emphasis on youth and rural regions. Data collected from the use of this page may be used in research.

On the 5-year anniversary of the start of the COVID pandemic, we remember all the lives lost to substance use disorders ...
03/11/2025

On the 5-year anniversary of the start of the COVID pandemic, we remember all the lives lost to substance use disorders across the world.
Here's hoping we can use what we learned from COVID to drastically increase access to medications that can save lives.

The 2020s have inarguably been Covid-19’s decade.  Since the coronavirus outbreak was acknowledged as a pandemic exactly five years ago, the pandemic

"New provisional data from CDC's National Vital Statistics System predict a nearly 24% decline in drug overdose deaths i...
03/03/2025

"New provisional data from CDC's National Vital Statistics System predict a nearly 24% decline in drug overdose deaths in the United States for the 12 months ending in September 2024, compared to the previous year."

New provisional data from CDC’s National Vital Statistics System predict a 24% decline in overdose

As part of his budget address, Scott proposed converting the Caledonia Community Work Camp in St. Johnsbury, an underuse...
02/07/2025

As part of his budget address, Scott proposed converting the Caledonia Community Work Camp in St. Johnsbury, an underused Department of Corrections facility, into a 15-bed recovery campus.

Governor Phil Scott pushes a new initiative to tackle substance misuse, a condition often overlooked as a mental health disorder.

The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based com...
02/07/2025

The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company Vertex Pharmaceuticals on Thursday.

The drug is the first new type of pain medicine approved in more than 20 years.

"Availability of commonly prescribed opioid analgesics was substantially lower in majority non-White communities than in...
02/06/2025

"Availability of commonly prescribed opioid analgesics was substantially lower in majority non-White communities than in majority White communities across all levels of socioeconomic deprivation."

nities. Using 2011 to 2021 national data from the Automated Reports and Consolidated Ordering System and generalized linear models, this study examined quarterly per capita distribution of oxycodone, hydrocodone, and morphine (in oral morphine milligram equivalents [MMEs]) by communities' racial/eth...

"One piece of the puzzle is supporting drug prevention programs that educate young people about synthetic opioids and pr...
02/05/2025

"One piece of the puzzle is supporting drug prevention programs that educate young people about synthetic opioids and preventable resources."

(Washington, DC) – U.S. Senators Jeanne Shaheen (D-NH), Ranking Member of the U.S. Senate...

"Veterans who receive care from both VA and non-VA providers—known as dual-system users—have an increased risk of Opioid...
02/04/2025

"Veterans who receive care from both VA and non-VA providers—known as dual-system users—have an increased risk of Opioid Use Disorder (OUD)... these findings suggest that within the dual-system users, patients with certain risk profiles warrant special attention."

The opioid crisis has disproportionately affected U.S. veterans, leading the Veterans Health Administration to implement opioid prescribing guidelines. Veterans who receive care from both VA and non-VA providers—known as dual-system users—have an increased risk of Opioid Use Disorder (OUD). The ...

"Vermont’s largest city has launched a new initiative that allows first responders to administer opioid addiction treatm...
01/21/2025

"Vermont’s largest city has launched a new initiative that allows first responders to administer opioid addiction treatment medication at the scene of overdoses."

Vermont’s largest city has launched a new initiative that allows first responders to administer opioid addiction treatment medication at the scene of overdoses. Research indicates it’s an effective way to get more people who struggle with opioid misuse into treatment.

12/02/2024

🧎‍♀️

🥳
11/25/2024

🥳

The projects include a methadone clinic in Aroostook County and a syringe service program in Hancock County.

This patient experience panel is 🔥
10/22/2024

This patient experience panel is 🔥

Address

46 Centerra Parkway, Suite 315
Lebanon, NH
03766

Opening Hours

Monday 8am - 4pm
Tuesday 8am - 4pm
Wednesday 8am - 4pm
Thursday 8am - 4pm
Friday 8am - 4pm

Telephone

+16036467086

Alerts

Be the first to know and let us send you an email when Northeast Node of the Clinical Trials Network posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Northeast Node of the Clinical Trials Network:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram